Fatty Liver Disease Strikes From Age 20: Blaming Patients Won’t Replace Prevention

15. november 2026

Fatty liver can progress without symptoms until irreversible damage occurs. Health professionals and patients are calling for early diagnoses, equitable access to therapies, and public strategies that address prevention beyond individual responsibility.

The liver does not warn. It does not hurt. It does not send alarm signals until the damage is advanced. It already affects almost 30% of the world population, according to estimates. Linked to overweight, diabetes, alcohol, hypertension, and high cholesterol, this condition increases the risk of cirrhosis; that chronic disease that replaces healthy tissue with fibrosis, impairing the liver’s ability to perform vital functions.

Undetected for decades, its consequences can be devastating: cirrhosis, liver cancer, or even the need for a transplant. The hepatic steatosis disease, known as fatty liver, affects a growing portion of the population and begins to appear in adults barely reaching 20 years of age. Experts warn of an underdiagnosed public health threat.

Fatty Liver

Doctors and patients are calling for stronger early detection and greater equity in access to treatments.

The fatty liver can develop over years without giving clear signals. When complications appear, some patients face cirrhosis, liver cancer, or the need for a transplant. Specialists also warn of cases of steatohepatitis in adults aged 20 and 30 years: waiting for the disease to be obvious is not a sufficient public health response.

Josep Maria Martínez understood the gravity of his situation after suffering extreme disorientation. The diagnosis revealed advanced liver cancer. A transplant saved his life.

His story directs criticism toward late diagnosis, stigma, and prevention that demands lifestyle changes without guaranteeing the conditions to do so. Repeating “eat better and exercise” cannot substitute for primary health care with resources or for public health policies.

The Fatty Liver Cannot Wait for a Complication to Appear

The fat buildup can be accompanied by inflammation — referred to as MASH when it is linked to metabolic dysfunction — and progress toward fibrosis, cirrhosis, or cancer. That evolution does not happen in all patients, but identifying who is at higher risk enables intervention before advanced damage occurs.

European medical guidelines recommend screening for fibrosis especially in people with type 2 diabetes, abdominal obesity accompanied by other metabolic factors, or persistent alterations in liver enzymes. An essential step is a staged assessment using tools like the FIB-4 and, when appropriate, elastography.

The evidence for decision-makers is concrete: facilitate those pathways, train professionals, and ensure follow-up. Left to chance in a single consultation, the diagnosis perpetuates missed opportunities. The absence of pain is no excuse and cannot become a reason to neglect risk.

Blaming the Patient Is Cheap; Prevention Demands Decisions

Jeffrey Lazarus, a researcher at ISGlobal, highlights the weight of sedentary lifestyles, alcohol, and unhealthy eating patterns. Reducing the fatty liver to a sum of personal choices lets everyone dodge uncomfortable questions about food pricing, advertising, and access to spaces for physical activity.

Municipalities have powers to act: healthy school meals, walkable environments, parks, and active mobility. A poster campaign is insufficient if municipal decisions continue to hinder the habits the recommendations promote.

The campaign must also address the association between liver disease and excessive alcohol consumption. The stigma surrounding the diagnosis can delay seeking care. Those in need require a clinical evaluation, not a moral interrogation that turns diagnosis into accusation.

Treatments Require Real Access, Not Just Approvals

Lazarus points to too many economic barriers to accessing treatments. The disease calls for transparency: approved indications, clinical criteria, financing, and availability must be explained without shifting the burden of deciphering the system onto the patient.

In the EU, resmetirom — Rezdiffra, from Madrigal Pharmaceuticals— has conditional approval for certain adults with MASH without cirrhosis and with moderate to advanced fibrosis, alongside diet and exercise. It is not blanket therapy for any fatty liver.

Yet, the decisive battle is fought in primary care and in the streets: without automated basic lab work, without removing the alcohol stigma, and without healthier urban environments, millions of people will continue to silently develop a disease that could be prevented before it is too late.

Pharmacological policy must respond to timelines and access conditions. Patients with fatty liver and health professionals need to know which options apply to each situation and how to obtain them.

A seemingly reassuring blood test result does not close the problem: normal transaminases do not rule out meaningful disease, and the FIB-4 score performs less well under 35 years of age.

In a pathology that also concerns young people, turning an isolated result into automatic exclusion can create a false sense of security. Detection requires clinical assessment and appropriate tests, not automatisms that leave patients out.

Eirik Lund

Based in Oslo, I write about climate, biodiversity and the connections between people and nature. I’m especially drawn to the ocean and the overlooked life along our coastlines. Through my articles, I aim to make environmental science accessible, explore the evidence behind the headlines and share the curiosity that keeps me looking closer.